Alcohol [Internet]. [cited 2024 Feb 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/alcohol. Accessed 25 Apr 2025.
Agabio R, Camposeragna A, Saulle R, Krupchanka D, Leggio L, Minozzi S. Combined pharmacological and psychosocial interventions for alcohol use disorder. Cochrane Libr. 2023;2023:CD015673.
Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, et al. The American Psychiatric Association Practice Guideline for the pharmacological treatment of patients with alcohol use disorder. Am J Psychiatry. 2018;175:86–90.
Witkiewitz K, Litten RZ, Leggio L. Advances in the science and treatment of alcohol use disorder. Sci Adv. 2019;5:eaax4043.
Article CAS PubMed PubMed Central Google Scholar
PhD RLA, PhD BS, PhD GE, PhD HE, Green RMA, Venegas ABS, et al. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. Am J Drug Alcohol Abuse. 2019;45:124–40.
Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen. J Rehabil Med. 2017;49:193–203.
Cott J, Carlsson A, Engel J, Lindqvist M. Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol. 1976;295:203–9.
Article CAS PubMed Google Scholar
Daoust M, Saligaut C, Lhuintre JP, Moore N, Flipo JL, Boismare F. GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol. 1987;4:469–72.
Article CAS PubMed Google Scholar
Addolorato G, Caputo F, Capristo E, Colombo G, Gessa GL, Gasbarrini G. Ability of baclofen in reducing alcohol craving and intake: II–Preliminary clinical evidence. Alcohol Clin Exp Res. 2000;24:67–71.
Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005;40:147–50.
Article CAS PubMed Google Scholar
Ameisen O. The End of My Addiction. New York: Farrar, Straus and Giroux, editor. 2008.
de Beaurepaire R, Sinclair JMA, Heydtmann M, Addolorato G, Aubin H-J, Beraha EM, et al. The use of baclofen as a treatment for alcohol use disorder: a clinical practice perspective. Front Psychiatry. 2018;9:708.
Rolland B, Simon N, Franchitto N, Aubin H-J. France grants an approval to baclofen for alcohol dependence. Alcohol Alcohol. 2020;55:44–5.
Garbutt JC. Use of baclofen for alcohol use disorders in the United States. Front Psychiatry. 2018;9:448.
Article PubMed PubMed Central Google Scholar
Agabio R, Sinclair JM, Addolorato G, Aubin H-J, Beraha EM, Caputo F, et al. Baclofen for the treatment of alcohol use disorder: the Cagliari Statement. Lancet Psychiatry. 2018;5:957–60.
Garbutt JC, Kampov-Polevoy AB, Pedersen C, Stansbury M, Jordan R, Willing L, et al. Efficacy and tolerability of baclofen in a U.S. community population with alcohol use disorder: a dose-response, randomized, controlled trial. Neuropsychopharmacology. 2021;46:2250–6.
Article CAS PubMed PubMed Central Google Scholar
Morley KC, Baillie A, Fraser I, Furneaux-Bate A, Dore G, Roberts M, et al. Baclofen in the treatment of alcohol dependence with or without liver disease: Multisite, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018;212:362–9.
Rozatkar AR, Kapoor A, Sidana A, Chavan BS. Clinical experience of baclofen in alcohol dependence: a chart review. Ind Psychiatry J. 2016;25:11–6.
Article PubMed PubMed Central Google Scholar
Bucknam W. Suppression of symptoms of alcohol dependence and craving using high-dose baclofen. Alcohol Alcohol. 2007;42:158–60.
Article CAS PubMed Google Scholar
Agabio R, Saulle R, Rösner S, Minozzi S. Baclofen for alcohol use disorder. Cochrane Database Syst Rev. 2023;1:CD012557.
Crippa A, Discacciati A, Bottai M, Spiegelman D, Orsini N. One-stage dose-response meta-analysis for aggregated data. Stat Methods Med Res. 2019;28:1579–96.
Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-Analysis of antipsychotic drugs for acute schizophrenia. Am J Psychiatry. 2020;177:342–53.
Furukawa TA, Cipriani A, Cowen PJ, Leucht S, Egger M, Salanti G. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry. 2019;6:601–9.
Article PubMed PubMed Central Google Scholar
Barrault C, Alqallaf S, Lison H, Lamote-Chaouche I, Bourcier V, Laugier J, et al. Baclofen combined with psychosocial care is useful and safe in alcohol-related cirrhosis patients: a real-life multicenter study. Alcohol Alcohol. 2023;58:117–24.
Article CAS PubMed Google Scholar
Murthy P, Shadakshari D, Mahadevan J, Chand PK. Management of alcohol use disorder in patients with alcoholic liver disease. J Clin Exp Hepatol. 2022;12:1514–26.
Article CAS PubMed PubMed Central Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
Article PubMed PubMed Central Google Scholar
Lee MR, Leggio L. Combined pharmacotherapies for the management of alcoholism: rationale and evidence to date. CNS Drugs. 2014;28:107–19.
Article CAS PubMed Google Scholar
Maisto SA, Pollock NK, Cornelius JR, Lynch KG, Martin CS. Alcohol relapse as a function of relapse definition in a clinical sample of adolescents. Addict Behav. 2003;28:449–59.
Cochrane Handbook for Systematic Reviews of Interventions [Internet]. [cited 2023 Mar 14]. Available from: https://training.cochrane.org/handbook/current. Accessed 25 Apr 2025.
Ostinelli EG, Efthimiou O, Luo Y, Miguel C, Karyotaki E, Cuijpers P, et al. Combining endpoint and change data did not affect the summary standardised mean difference in pairwise and network meta-analyses: an empirical study in depression. Res Synth Methods [Internet]. 2024. https://doi.org/10.1002/jrsm.1719.
Kotake K, Hosokawa T, Tanaka M, So R, Banno M, Kataoka Y, et al. Efficacy and safety of alcohol reduction pharmacotherapy according to treatment duration in patients with alcohol dependence or alcohol use disorder: a systematic review and network meta-analysis. Addiction [Internet]. 2024. https://doi.org/10.1111/add.16421.
Johnson BA, DiClemente CC, Ait-Daoud N, Stoks SM. In: Brief Behavioral Compliance Enhancement Treatment (BBCET) manual. In: Johnson BA, Ruiz P, Galanter M, editors. Handbook of clinical alcoholism treatment. Baltimore: Lippincott Williams & Wilkins; 2003. p. 282–301.
Starosta AN, Leeman RF, Volpicelli JR. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract. 2006;12:80–9.
Article PubMed PubMed Central Google Scholar
Roche AM, Freeman T. Brief interventions: good in theory but weak in practice. Drug Alcohol Rev. 2004;23:11–8.
Carroll KM, Kiluk BD. Cognitive behavioral interventions for alcohol and drug use disorders: through the stage model and back again. Psychol Addict Behav. 2017;31:847–61.
Article PubMed PubMed Central Google Scholar
Kumar S, Srivastava M, Srivastava M, Yadav JS, Prakash S. Effect of motivational enhancement therapy (MET) on the self efficacy of individuals of alcohol dependence. J Family Med Prim Care. 2021;10:367–72.
Article PubMed PubMed Central Google Scholar
Pettinati HM, Volpicelli JR, Pierce JD Jr, O’Brien CP. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis. 2000;19:71–83.
Comments (0)